RT Journal Article
T1 Therapeutic Approach to Alzheimer's Disease: Current Treatments and New Perspectives.
A1 Pardo-Moreno, Teresa
A1 Gonzalez-Acedo, Anabel
A1 Rivas-Dominguez, Antonio
A1 Garcia-Morales, Victoria
A1 Garcia-Cozar, Francisco Jose
A1 Ramos-Rodriguez, Juan Jose
A1 Melguizo-Rodriguez, Lucia
K1 Alzheimer’s disease
K1 Aβ pathology
K1 Dementia
K1 Drugs
K1 Pharmacology
K1 Tau pathology
AB Alzheimer's disease (AD) is the most common cause of dementia. The pathophysiology of this disease is characterized by the accumulation of amyloid-β, leading to the formation of senile plaques, and by the intracellular presence of neurofibrillary tangles based on hyperphosphorylated tau protein. In the therapeutic approach to AD, we can identify three important fronts: the approved drugs currently available for the treatment of the disease, which include aducanumab, donepezil, galantamine, rivastigmine, memantine, and a combination of memantine and donepezil; therapies under investigation that work mainly on Aβ pathology and tau pathology, and which include γ-secretase inhibitors, β-secretase inhibitors, α-secretase modulators, aggregation inhibitors, metal interfering drugs, drugs that enhance Aβ clearance, inhibitors of tau protein hyperphosphorylation, tau protein aggregation inhibitors, and drugs that promote the clearance of tau, and finally, other alternative therapies designed to improve lifestyle, thus contributing to the prevention of the disease. Therefore, the aim of this review was to analyze and describe current treatments and possible future alternatives in the therapeutic approach to AD.
PB MDPI
SN 1999-4923
YR 2022
FD 2022-05-24
LK http://hdl.handle.net/10668/21551
UL http://hdl.handle.net/10668/21551
LA en
NO Pardo-Moreno T, González-Acedo A, Rivas-Domínguez A, García-Morales V, García-Cozar FJ, Ramos-Rodríguez JJ, et al. Therapeutic Approach to Alzheimer's Disease: Current Treatments and New Perspectives. Pharmaceutics. 2022 May 24;14(6):1117
NO This work was funded in part by P20-01293 from Junta de Andalucía, Spain, PECART-0096-2020 from Junta de Andalucía, Spain, and PID2020-117544RB-100 from the Ministry of Science andInnovation, Spain.
DS RISalud
RD Apr 12, 2025